Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-17T21:00:43.268Z Has data issue: false hasContentIssue false
  • English
  • Français

Metabolic side effects of atypical antipsychotics in older adults

Published online by Cambridge University Press:  25 May 2018

Emme Chacko ,
Stephen Boyd  and
Rinki Murphy
Emme Chacko
Affiliation:
Mental Health Service for Older People, Auckland District Health Board, Auckland, New Zealand
Stephen Boyd*
Affiliation:
Mental Health Service for Older People, Auckland District Health Board, Auckland, New Zealand
Rinki Murphy
Affiliation:
Auckland Diabetes Centre, Auckland District Health Board, Auckland, New Zealand Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
*
Correspondence should be addressed to: Dr. Stephen Boyd, Mental Health Services for Older People, Building 14, Greenlane Clinical Centre, Private Bag 92189, Auckland, New Zealand. Email: sboyd@adhb.govt.nz.
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

The atypical antipsychotics (AAPs) are associated with a recognized class effect of glucose and lipid dysregulation. The use of these medications is rapidly increasing in elderly patients with, and without, dementia. However, the metabolic risks specific to elderly remain poorly studied.

Methods:

Design: A case-control study.

Setting: Psychogeriatric service in Auckland, New Zealand.

Participants: Elderly patients either receiving AAP treatment (cases) or not (controls) between 1 Jan 2008 and 1 Jan 2014.

Main outcome measures: metabolic data of glucose, HbA1c, lipids, and cardiovascular events and death. The data were analyzed using t-tests and linear regression models for each metabolic outcome.

Results:

There were 330 eligible cases and 301 controls from a total study population of 5,307. There was a statistically significant change in the HbA1c over time, within the cases group of −1.14 mmol/mol (p = 0.018, 95% CI −0.19 to −2.09). Also statistically significant was the reduction in total cholesterol of −0.13 mmol/L (p = 0.036, 95% CI −0.008 to −0.245). The only significant difference found between cases and controls was in the change in cholesterol ratio of 0.16 mmol/L between groups (95%CI 0.01–0.31, p = 0.036).

Conclusions:

AAP use was not associated with any clinically significant change in metabolic outcomes in this study population.

Keywords

elderlyatypical antipsychoticsmetabolic changes
Type
Original Research Article
Information
International Psychogeriatrics , Volume 30 , Issue 10: Issue Theme: Mild Cognitive Impairment , October 2018 , pp. 1557 - 1566
Copyright
Copyright © International Psychogeriatric Association 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Administration FDA (2005). Antipsychotics: conventional and atypical. http://www.fda.gov.Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm110212.htm; last accessed 3 August 2013.Google Scholar
Alexopoulous, G., Streim, J., Carpenter, D. and Docherty, J. (2004). Using antipsychotic agents in older patients. Journal of Clinical Psychiatry, 65 (Suppl. 2), 5–99.Google Scholar
Allison, D. et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156, 1686–1696.Google Scholar
Alvarez-Jimenez, M. et al. (2008). Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs, 22, 547–562.Google Scholar
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington DC: American Psychiatric Association.Google Scholar
Association CP (2012). Compendium of Pharmaceuticals and Specialties (CPS). Canada: Canadian Pharmacists Association.Google Scholar
Balf, G. (2008). Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics. American Journal of Psychiatry, 165, 1206–1207.Google Scholar
Barak, Y. and Aizenberg, D. (2003). Effects of olanzapine on lipid abnormalities in elderly psychotic patients. Drugs & Aging, 20, 893–896.Google Scholar
Bissells, G., Staekenborg, S., Brunner, E., Brayne, C. and Scheltens, P. (2006). Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurology, 16, 693–704.Google Scholar
Braadvedt, G. et al. (2012). Understanding the new HbA1c units for the diagnosis of Type 2 diabetes. The New Zealand Medical Journal, 125, 70–80.Google Scholar
Cohn, T. and Sernyak, M. (2006). Metabolic monitoring for patients treated with antipsychotic medications. Canada Journal of Psychiatry, 51, 492–501.Google Scholar
Copeland, L., Parchman, M., Zeber, J., Lawrence, V., Downs, J. and Miller, A. (2010). Prediabetes assessment and follow-up in older veterans with schizophrenia. American Journal of Geriatric Psychiatry, 18, 887–896.Google Scholar
De Deyn, P. et al. (2004). Olanzapine versus placebo in the treatment of psychosis with or without associated behavioural disturbances in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry, 19, 115–126.Google Scholar
Deberdt, W. et al. (2005). Comparsion of olanzapine and risperidone in the treatment of psychosis and associated behavioural disturbances in patients with dementia. American Journal of Geriatric Psychiatry, 13, 722–730.Google Scholar
Dixon, L. et al. (2000). Prevalence and correlates of diabetes in national schizophrenia samples. Schizophrenia Bulletin, 26, 903–912.Google Scholar
Erickson, S. C. et al. (2012). New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder. Journal of the American Geriatrics Society, 60, 474–479.Google Scholar
Feldman, P., Hay, L., Deberdt, W. and Kennedy, J. (2004). Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. Journal of American Medical Directors Association, 5, 38–46.Google Scholar
Goldberg, R. (2001). Weight variance associated with atypical neuroleptics in nursing home dementia patients. Journal of American Medical Directors Association, 24, 201–209.Google Scholar
Guenette, M., Hahn, M., Cohn, T., Teo, C. and Remington, G. (2013). Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology, 226, 1–12.Google Scholar
Guenette, M. D., Chintoh, A., Remington, G. and Hahn, M. (2014). Atypical antipsychotic-induced metabolic disturbances in the elderly. Drugs & Aging, 31, 159–184.Google Scholar
Gurevitz, S., Costakis, T. and Leiter, J. (2009). Do atypical antipsychotics cause weight gain in nursing home dementia residents? Consultant Pharmacist, 24, 201–209.Google Scholar
Hammerman, A., Dreiher, J., Klang, S., Cunitz, H., Cohen, A. and Goldfracht, M. (2008). Antipsychotics and diabetes: an age-related association. Annals of Pharmacotherapy, 42, 1316–1322.Google Scholar
Harris, E. and Barraclough, B. (1998). Excess mortality of mental disorder. British Journal of Psychiatry, 173, 11–53.Google Scholar
Holt, R. (2008). The metabolic side effects of antipsychotics in elderly patients. Geriatric Medicine, July, 399–402.Google Scholar
Hwang, J., Yang, C., Lee, T. and Thai, S. (2003). The efficacy and safety of olanzapine for the treatment of geriatric psychosis. Journal of Clinical Psychopharmacology, 23, 113–118.Google Scholar
Kennedy, J., Bymaster, F., Schuh, L. and Calligaro, D. (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. International Journal of Geriatric Psychiatry, 16, S33–S61.Google Scholar
Kinon, B., Basson, B. R., Gilmore, J. A. and Tollefson, G. D. (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry, 62, 92–100.Google Scholar
Kisely, S., Cox, M., Campbell, L., Cooke, C. and Gardner, D. (2009). An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients. Canada Journal of Psychiatry, 54, 269–274.Google Scholar
Lipscombe, L. et al. (2009). Antipsychotic drugs and hyperglycemia in older patients with diabetes. Archives of Internal Medicine, 169, 1282–1289.Google Scholar
Lipscombe, L. et al. (2011). Antipsychotic drugs and the risk of hyperglyecemia in older adults without diabetes: a population-based observational study. American Journal of Geriatric Psychiatry, 19, 1026–1033.Google Scholar
Marder, S. et al. (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry, 16, 1334–1349.Google Scholar
Martinez, R., Peris Martí, J. F., Gomar Fayos, J., Navarro Gosalbez, M., Quintana Vargas, I. and Muelas Tirado, J. (2010). Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalance of metabolic alterations. Farmacia Hospitalaria, 24, 139–147.Google Scholar
McIntyre, R., McCann, S. and Kennedy, S. (2001). Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Canada Journal of Psychiatry, 46, 273–281.Google Scholar
Mitchell, A., Delaffon, V., Vancampfort, D., Correll, C. and De Hert, M. (2012). Guideline concordant monitoring of metabolic risk in peopel treated with antipsychotic medication: a systematic review and meta-analysis of screening practices. Psychological Medicine, 42, 125–147.Google Scholar
Morris, J. (1993). The clinical dementia rating (CDR): current version and scoring rules. Neurology, 43, 2412–2414.Google Scholar
Newcomer, J. (2005). Second generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 19 (Suppl. 1), 1–93.Google Scholar
Newman, S. and Bland, R. (1991). Mortality in a cohort of patients with schizophrenia: a record linkage study. Canadian Journal of Psychiatry, 36, 239–245.Google Scholar
Sernyak, M., Leslie, D., Alarcon, R., Losonczy, M. and Rosenheck, R. (2002). Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Americal Journal of Psychiatry, 159, 561–566.Google Scholar
Smith, E. et al. (2008). Weight gain during olanzapine treatment for psychotic depression: effects of dose and age. International Journal of Clinical Psychopharmacology, 23, 130–137.Google Scholar
Street, J., Clark, W. and Gannon, K. (2000). Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind randomized placebo-controlled trial. The HGEU Study Group. Archives of General Psychiatry Journal, 57, 968–976.Google Scholar
Vidarsdottir, S., deLeeuw van Weenen, J., Frolich, M., Roelfzema, F., Romijn, J. and Pijl, H. (2010a). Effects of olanzapine and haloperidol on the metabolic status of healthy men. Journal of Clinical Endocrinology and Metabolism, 95, 118–125.Google Scholar
Vidarsdottir, S., Vlug, P., Roelfzema, F., Frolich, M. and Pijl, H. (2010b). Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. Journal of Clinical Psychiatry, 71, 1205–1211.Google Scholar
Vik-Mo, A., Birenaes, A., Ferno, J., Jonsdottir, H., Andreassen, O. and Steen, V. (2008). Increased expression or biosynthesis genes in peripheral blood cells of olanzapine-treated patients. International Journal of Neuropsychopharmacology, 11, 679–684.Google Scholar
White, H., Pieper, C. and Schmader, K. (1998). The association of weight change in Alzheimer's disease with severity of disease and mortality: a longitudinal analysis. Journal of the American Geriatrics Society, 46, 1223–1227.Google Scholar
Woods, S. W. (2013). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry, 64 (6), 663–667.Google Scholar
Yang, C., Tsai, S. and Hwang, J. (2005). The efficacy and safety of quetiapine for treatment of geriatric psychosis. Journal of Psychopharmacology, 19, 661–666.Google Scholar
Zheng, L., Mack, W., Dagerman, K. and Hsiao, J. (2009). Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study. American Journal of Psychiatry, 166, 583–590.Google Scholar